Matthieu Rouffet, Ph.D.

Co-Chair, Chemistry Department
Professor of Chemistry

Dr. Matthieu Rouffet is a medicinal chemist who was born and raised in France. After completing his Ph.D. in pharmaceutical chemistry at the University of Reims, he moved to San Diego to start a postdoctoral fellowship position at UCSD under the supervision of Professor Seth. M. Cohen. During that time, he worked on the development of inhibitors of biologically relevant targets.


  • Ph.D., Organic Chemistry, School of Pharmacy, Reims, France
  • M.S., Organic Chemistry, University of Reims, France
  • B.S., Chemistry, University of Reims, France

Courses Taught

  • Intro to General, Organic, and Biological Chemistry – CHE 1003
  • Intro to General, Organic, and Biological Chemistry Lab – CHE 1003L
  • Organic Chemistry I Lab – CHE 2094L
  • Bioinorganic Chemistry – CHE 4066
  • Chemistry Seminar – CHE 4095
  • Research in Chemistry – CHE 4099
  • Physical Science – PSC 1014
  • Advanced Organic Chemistry – CHE 4053

Experience in Field

  • Research interest: synthesis and biological evaluation of metal binding inhibitors of metalloenzymes involved in diseases such as anthrax infection, malaria, and tuberculosis
  • Point Loma Nazarene University (San Diego, CA), Associate Professor, 2011 – present
  • University of California at San Diego (San Diego, CA), Postdoctoral Associate, 2009 – 2011
  • School of Pharmacy, Reims (Reims, France), Graduate Researcher, 2005 – 2008
  • University of York (United Kingdom), Undergraduate Researcher, 2004

Professional and Community Involvement

  • Member, American Chemical Society, 2009 – present
  • Member, French Chemical Society, 2005 – 2008

Awards and Honors

  • Ph.D. scholarship from the Region of Champagne-Ardennes (France), 2005 – 2008
  • Master of Science merit scholarship, 2004 – 2005

Dissertations, Presentations, and Publications

  • "Perez, C.; Li, J.; Parlati, F.; Rouffet, M.; Ma, Y.; Mackinnon, A, L,; Chou, T,; Deshaies, R, J.; and Cohen, S. M. ""Discovery of an Inhibitor of the Proteasome Subunit Rpn11."" 
  • J. Med. Chem., 2017, accepted"
  • Abass, G.; Elson, D.; Dorrell, M.; Rouffet, M. “Towards the synthesis of MTX-phenylalanine derivatives for the treatment of glioblastoma in antibody-directed enzyme prodrug therapy” American Chemical Society National Meeting, San Diego, 2016. (Poster)
  • "Voss, C. L.; Rouffet, M. “Design and Synthesis of 2-(2-sulfonamido)phenylbenzimidazole derivatives as Potential IspF Inhibitors.” 
  • American Chemical Society National Meeting, San Diego, 2016. (Poster)"
  • Tanakit, A.; Rouffet, M.; Martin, D. P. and Cohen, S. M, “Investigating chelating sulfonamides and their use in metalloproteinase inhibitors”, Dalton Trans., 2012, 41, 6507. (paper)
  • Rouffet, M. and Cohen, S. M., “Emerging trends in metalloprotein inhibition”, Dalton Trans., 2011, 40, 3445 (paper)
  •  Zhou, H.; Parlati, F.;  Rouffet, M.; Emberley, E.; Deshaies, R. J.; Cohen, S. M. "Compositions and methods for jamm protein inhibition." 2014, US 20140235548 A1 (patent)
  • Rouffet, M.; De Oliveira, C. A. F.; Udi, Y.; Agrawal A.; Sagi, I.; McCammon, J. A. and Cohen, S.M. “From Sensors to Silencers: Quinoline- and Benzimidazole-Sulfonamides as Inhibitors for Zinc Proteases.” J. Am. Chem. Soc., 2010, 132, 8232–8233 (paper)